 Shares of Intra-Cellular Therapies NASDAQ:ITCI fell 2 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 41.18 year over year to 0.96, which missed the estimate of 0.91.Revenue of 1,907,000 higher by 0.00 from the same period last year, which missed the estimate of 3,030,000.Guidance Earnings guidance hasnt been issued by the company for now.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: Aug 10, 2020View more earnings on ITCITime: 08:30 AMET Webcast URL: Stock Performance 52-week high: 43.5652-week low: 6.75Price action over last quarter: Up 7.13Company Overview Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The companys business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.See more from Benzinga Earnings Scheduled For August 10, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 